NDC-11 (Package) (Descending) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
81864-0103-30 | 81864-0103 | Momelotinib | Ojjaara | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Sept. 15, 2023 | In Use | |
81864-0102-30 | 81864-0102 | Momelotinib | Ojjaara | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Sept. 15, 2023 | In Use | |
81864-0101-30 | 81864-0101 | Momelotinib | Ojjaara | 200.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Sept. 15, 2023 | In Use | |
81643-9270-01 | 81643-9270 | Floxuridine | Floxuridine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intra-arterial | June 9, 2022 | In Use | |
81607-0006-07 | 81607-0006 | Arsenic trioxide | ARSENIC TRIOXIDE | 2.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | May 31, 2023 | In Use | |
81607-0005-11 | 81607-0005 | Arsenic trioxide | ARSENIC TRIOXIDE | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | May 31, 2023 | In Use | |
81565-0202-02 | 81565-0202 | DEXAMETHASONE SODIUM PHOSPHATE | Dexamethasone Sodium Phosphate | 4.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Dec. 15, 2021 | In Use | |
81561-0413-05 | 81561-0413 | asparaginase | ERWINASE | 10000.0 [iU]/mL | Chemotherapy | Miscellaneous Agent | Enzyme | Intramuscular, Intravenous | June 1, 2021 | In Use | |
81298-8114-01 | 81298-8114 | Cyclophosphamide | Cyclophosphamide | 2.0 g/100mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Jan. 1, 2022 | In Use | |
81298-8112-01 | 81298-8112 | Cyclophosphamide | Cyclophosphamide | 1.0 g/50mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Jan. 1, 2022 | In Use | |
81298-8110-01 | 81298-8110 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/25mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Jan. 1, 2022 | In Use | |
81298-5785-03 | 81298-5785 | Triamcinolone Acetonide | Triamcinolone Acetonide | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-arterial, Intramuscular | May 2, 2022 | In Use | |
81298-5783-03 | 81298-5783 | Triamcinolone Acetonide | Triamcinolone Acetonide | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-arterial, Intramuscular | May 2, 2022 | In Use | |
81298-5781-05 | 81298-5781 | Triamcinolone Acetonide | Triamcinolone Acetonide | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-arterial, Intramuscular | May 2, 2022 | In Use | |
80978-0111-06 | 80978-0111 | Nelarabine injection | NELARABINE | 250.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | April 12, 2023 | In Use | |
80739-0812-18 | 80739-0812 | Adagrasib | KRAZATI | 200.0 mg/1 | Immunotherapy | RAS Inhibitor | KRAS G12C | Oral | Dec. 12, 2022 | In Use | |
80739-0812-12 | 80739-0812 | Adagrasib | KRAZATI | 200.0 mg/1 | Immunotherapy | RAS Inhibitor | KRAS G12C | Oral | Dec. 12, 2022 | In Use | |
80725-0712-15 | 80725-0712 | Dutasteride | AVODART | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 15, 2022 | In Use | |
80725-0712-04 | 80725-0712 | Dutasteride | AVODART | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec. 15, 2022 | In Use | |
80725-0630-25 | 80725-0630 | Thioguanine | TABLOID | 40.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | May 15, 2023 | In Use | |
80725-0620-25 | 80725-0620 | Busulfan | MYLERAN | 2.0 mg/1 | Chemotherapy | Alkylating Agent | Alkylsulfonate | Oral | May 15, 2023 | In Use | |
80725-0610-25 | 80725-0610 | Chlorambucil | LEUKERAN | 2.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | May 15, 2023 | In Use | |
80725-0600-18 | 80725-0600 | Flutamide | Eulexin | 125.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Nov. 12, 2021 | In Use | |
80446-0401-01 | 80446-0401 | TEBENTAFUSP | KIMMTRAK | 100.0 ug/.5mL | Immunotherapy | T Cell Receptor (TCR) | HLA-A*02:01 | Intravenous | Jan. 26, 2022 | In Use | |
80425-0346-03 | 80425-0346 | Dexamethasone | Dexamethasone | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | July 31, 2023 | In Use | |
80425-0346-02 | 80425-0346 | Dexamethasone | Dexamethasone | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | July 31, 2023 | In Use | |
80425-0346-01 | 80425-0346 | Dexamethasone | Dexamethasone | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | July 31, 2023 | In Use | |
80425-0328-01 | 80425-0328 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 24, 2023 | In Use | |
80425-0262-01 | 80425-0262 | Triamcinolone acetonide | Triamcinolone acetonide | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intramuscular | Feb. 15, 2023 | In Use | |
80425-0261-01 | 80425-0261 | Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 10.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Feb. 16, 2023 | In Use | |
80425-0255-01 | 80425-0255 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 11, 2023 | In Use | |
80425-0242-02 | 80425-0242 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 11, 2023 | In Use | |
80425-0232-01 | 80425-0232 | Dexamethasone Sodium Phosphate, Povidine Iodine | DoubleDex Kit | 10.0 mg/ml | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous, Topical | May 12, 2023 | In Use | |
80425-0231-01 | 80425-0231 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 11, 2023 | In Use | |
80425-0230-01 | 80425-0230 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 11, 2023 | In Use | |
80425-0228-01 | 80425-0228 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 11, 2023 | In Use | |
80425-0227-01 | 80425-0227 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 11, 2023 | In Use | |
80425-0222-01 | 80425-0222 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 12, 2023 | In Use | |
80425-0105-03 | 80425-0105 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 16, 2023 | In Use | |
80425-0105-02 | 80425-0105 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 30, 2023 | In Use | |
80425-0105-01 | 80425-0105 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 29, 2001 | In Use | |
80425-0075-05 | 80425-0075 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 31, 2007 | In Use | |
80425-0075-04 | 80425-0075 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 31, 2007 | In Use | |
80425-0075-03 | 80425-0075 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 31, 2007 | In Use | |
80425-0075-02 | 80425-0075 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 31, 2007 | In Use | |
80425-0075-01 | 80425-0075 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 31, 2007 | In Use | |
80425-0074-05 | 80425-0074 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 16, 2020 | In Use | |
80425-0074-04 | 80425-0074 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 16, 2020 | In Use | |
80425-0074-03 | 80425-0074 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 16, 2020 | In Use | |
80425-0074-02 | 80425-0074 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 16, 2020 | In Use |
Found 10,000 results in 4 milliseconds — Export these results